WallStreetZenWallStreetZen

NASDAQ: ENTA
Enanta Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Enanta Pharmaceuticals revenue was $65.32M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $15.1M, down 17.4% from last quarter. For the last reported fiscal year 2025 ending Sep 30, 2025, ENTA annual revenue was $65.3M, with -3.4% growth year-over-year.

ENTA past revenue growth

How has ENTA's revenue growth performed historically?

Company
-3.42%
Industry
258.54%
Market
21.98%
ENTA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ENTA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ENTA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ENTA revenue history

Current Revenue
$65.3M
Current Earnings
-$81.9M
Current Profit Margin
-125.4%

Be the first to know when ENTA announces revenue.

ENTA Revenue History By Year

ENTA Yearly RevenueENTA RevenueENTA ChangeENTA Revenue Growth
2025-09-30$65.32M-$2.31M-3.42%
2024-09-30$67.64M-$11.57M-14.61%
2023-09-30$79.20M-$6.96M-8.07%
2022-09-30$86.16M-$10.91M-11.24%
2021-09-30$97.07M-$25.40M-20.74%
2020-09-30$122.47M-$82.72M-40.31%
2019-09-30$205.20M-$1.43M-0.69%
2018-09-30$206.63M$103.81M+100.97%
2017-09-30$102.81M$14.55M+16.48%
2016-09-30$88.27M-$72.61M-45.13%
2015-09-30$160.88M$113.14M+236.98%
2014-09-30$47.74M$15.69M+48.94%
2013-09-30$32.05M-$9.65M-23.15%
2012-09-30$41.71M-$176.00k-0.42%
2011-09-30$41.88M$19.12M+83.99%
2010-09-30$22.76MN/AN/A

1 of 2

Enanta Pharmaceuticals Revenue FAQ

What was ENTA's revenue last quarter?

On Invalid Date, Enanta Pharmaceuticals (NASDAQ: ENTA) reported Q3 2025 revenue of $15.13 million up 3.55% year over year. In the same quarter last year, Enanta Pharmaceuticals's revenue was $14.61 million.

What was Enanta Pharmaceuticals's revenue in 2025?

Enanta Pharmaceuticals's annual revenue for the twelve months ending Sep 30, 2025 was $65.32 million, a 3.42% decrease year over year.

How much does Enanta Pharmaceuticals make in a day?

Based on Enanta Pharmaceuticals annual revenue for the past five years, ENTA makes an average of $216,655.89 per day.

What was Enanta Pharmaceuticals's annual revenue growth in the past year?

As of Q4 2025, Enanta Pharmaceuticals's revenue has grown -3.42% year over year. This is 261.96 percentage points lower than the US Biotechnology industry revenue growth rate of 258.54%. Enanta Pharmaceuticals's revenue in the past year totaled $65.32 million.

How much does Enanta Pharmaceuticals make in a year?

Enanta Pharmaceuticals's revenue by year for the past five years is:
  • Enanta Pharmaceuticals's revenue for the twelve months ending Sep 30, 2025 was $65.32 million, a 3.42% decrease year over year.
  • Enanta Pharmaceuticals's annual revenue for Sep 30, 2024 was $67.64 million, a 14.61% decrease from 2023.
  • Enanta Pharmaceuticals's annual revenue for 2023 was $79.20 million, a 8.07% decrease from 2022.
  • Enanta Pharmaceuticals's annual revenue for 2022 was $86.16 million, a 11.24% decrease from 2021.
  • Enanta Pharmaceuticals's annual revenue for 2021 was $97.07 million, a 20.74% decrease from 2020.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.